Produced By Deanna Utroske, 2
This month, multinational bioprinting technologies company Cellink announced having reached a deal to acquire Cytena for €30.25 million. The Freiburg, Germany – based venture specialises in single-cell printing technology. And the deal will expand Cellink’s capabilities in both pharma and cosmetics.
Cellink got its start in 2016 and is headquartered in Boston, Massachusetts, (in the US) where a lot of biotech businesses are located. The company makes and commercializes bioprinting technologies for use in academic research and industry. Bioprinting is essentially 3-dimentional printing technology that incorporates live cells and is used to create tissue and other components.
Kirsty Doolan 12 February 2025 We examine what's new in tropical and ingestible beauty products…
10 February 2025 IFF announces the launch of its new artificial intelligence (AI)-powered search tool:…
Renata Martins 6 February 2025 The global cosmetics market is evolving rapidly with an influx…